drugset / Trial / NCT00003450
Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer
Phase 1
Completed
University of Texas Southwestern Medical Center
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Inserting the p53 gene into a person's cancer cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. PURPOSE: Phase I trial to study the effectiveness of gene therapy using the p53 gene in treating patients with advanced recurrent or persistent ovarian cancer or primary peritoneal cavity cancer.
Timeline
- Start
- 1998-09
- Primary completion
- 1999-01
- Completion
- 1999-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CONTUSUGENE LADENOVEC | Unknown | — | Other |